AstraZeneca and Amgen’s experimental drug tezepelumab reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.
Regeneron Pharmaceuticals said an independent panel found the company’s Covid-19 antibody cocktail to have “clear clinical efficacy” in reducing the rates of hospitalization and deaths in patients.
Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis, evaluated against placebo and Amgen’s Otezla (apremilast).
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents in a Phase III trial.
Biohaven Pharmaceuticals’ third-generation prodrug troriluzole did not show a statistical improvement for patients when compared to those on placebo at the 48-week marker as a symptomatic treatment in mild-to-moderate Alzheimer’s disease (AD).
Novavax Inc. started a large late-stage study of the company’s experimental Covid-19 vaccine in the United States after delaying the trial twice due to issues in scaling up the manufacturing process.
AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
Moderna announced plans to submit the company’s request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EUA) for the Covid-19 vaccine mRNA-1273 on Nov. 30.
A Phase III trial of NurOwn (MSC-NTF cells), BrainStorm Cell Therapeutics’ investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the product and placebo for improving scores on a revised ALS functional rating scale (ALSFRS-R) that measures the severity of the disease.
Cytokinetics Inc. said a pivotal trial of the experimental heart failure drug the company is developing with Amgen Inc. showed a slightly higher rate of cardiovascular-related death for patients given the medicine compared to those on a placebo.
